Category: Health Science
-
![Revive Therapeutics (RVV.C) licenses patent on long COVID biomarkers]()
Revive Therapeutics (RVV.C) licenses patent on long COVID biomarkers
Revive Therapeutics (RVV.C), a company that specializes in creating treatments and tests for diseases that don’t have many existing options available, has made a deal with a health research group called Lawson Health Research Institute to license the rights to use special signals in the blood—called biomarkers—that can show if someone has ‘long COVID.’ “We…
-
![Revive Therapeutics (RVV.C): Covid came, Covid went, but Revive is still fighting]()
Revive Therapeutics (RVV.C): Covid came, Covid went, but Revive is still fighting
Back at the dawn of Covid-19, a load of public companies started pumping out news releases that claimed they were going to be entering the medical space. In the best tradition of Howe Street, long dormant mining companies suddenly became med-tech deals, hawking everything from clear plastic checkout counter dividers to virus sniffing doorways to…
-
![Core Story: FendX Technologies (FNDX.C) repels and kills pathogens and viruses]()
Core Story: FendX Technologies (FNDX.C) repels and kills pathogens and viruses
We went after this company as a client because there are three things about it that make me swoon. 1: The CEO has done it all before, in this industry, and has more knowledge about her domain than most 2: The product is needed, necessary, cutting edge, and quickly developing with their academic partners 3:…
-
![Multi-Company Wrap: Watching the watchlist so you don’t have to]()
Multi-Company Wrap: Watching the watchlist so you don’t have to
We have some 29 companies on our watchlist, all in a variety of sectors, that we’re covering at any one time. Some are clients, some not, some are on deaths door, some are skyrocketing, so we’ve decided to wrap them all up into one monthly wrap so you can keep track of everything at once.…
-
![Pubco cocaine is here: What does it mean, who’s in, and who’s real?]()
Pubco cocaine is here: What does it mean, who’s in, and who’s real?
I recently listened to a podcast episode of Search Engine with PJ Vogt, and I REALLY got into it. The episode was titled, “Why are drug dealers putting fentanyl in everything?” I’d asked myself the same question many times – why kill your customers? I’d recommend you go listen because the answer is a lot…
-
![The Core Story: Medexus Pharmaceutical (MDP.T) just grows and grows]()
The Core Story: Medexus Pharmaceutical (MDP.T) just grows and grows
Continuing out Core Story program, today’s exploration is a company we just can’t get enough of, Medexus Pharmaceuticals (MDP.T). CEO Ken D’Entremont has nailed his milestones the last 18 months, continued running revenues up, kept expenses low, and restructured convertible debt to remain in control os his company’s direction going forward. They’ve blasted through a…
-
![Innovation and Growth: Canada’s Thriving Pharmaceutical Industry in the Global Market]()
Innovation and Growth: Canada’s Thriving Pharmaceutical Industry in the Global Market
Even though the COVID-19 pandemic posed challenges for healthcare and life sciences companies, Canada’s pharmaceutical industry continued to thrive, thanks to the government’s investments in pharma which buttressed the industry against the storm. Comprising a 2.1% share of the global pharmaceutical market, Canada now ranks as the 9th largest market worldwide. There’s no resting on…
-
![Medexus Pharmaceuticals (MDP.TO): A growing core business breaking company records]()
Medexus Pharmaceuticals (MDP.TO): A growing core business breaking company records
*originally published 01-16-23 Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company. They are not biotech. There is no research and development here. Medexus is all about sales and marketing, bringing over drugs that are already licensed in Western Europe and then bringing them to North America. A very smart business model which has seen Medexus carve…
-
![Medexus Pharmaceuticals (MDP.TO) Q2 2023 revenue expected to exceed US$27 million]()
Medexus Pharmaceuticals (MDP.TO) Q2 2023 revenue expected to exceed US$27 million
Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company that has been making big moves on the charts. The company is not a biotech company. They do not do research and development, but instead bring over drugs that are already licensed in Western Europe to North America which sees them carve out a nice and profitable…
-
![Medexus Pharmaceutical (MDP.T) readies for powerful year of growth in specialty pharma sector]()
Medexus Pharmaceutical (MDP.T) readies for powerful year of growth in specialty pharma sector
Big pharma firms like Abbvie can offer incredible product growth potential to investors, but they also saddle shareholders with tremendous risk in terms of regulatory approval and capital cost. According to a recent study which tracked the success rates of clinical drug development through to FDA approval between 2006-2015, just 9.6% of the drug candidates…
